Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center

Background Rectal gastrointestinal stromal tumor (GIST) is a rare digestive disease that has a distinct malignant tendency compared to that of gastric-derived GIST. At present, there is still no standard, and the surgical approach to rectal GIST is controversial. Methods The clinicopathological data and prognosis of rectal GIST patients admitted to the Sixth Affiliated Hospital of Sun Yat-sen University from 1998.01.01 to 2018.12.31 were collected retrospectively. All cases were divided into either the transanal (TA) group or the nontransanal (NTA) group. Results A total of 537 GIST cases were treated in 10 years, including 82 rectal GIST cases (64 cases underwent surgical resection, including 29 cases in the TA group and 35 cases in the NTA group). Preoperative neoadjuvant therapy (P=0.003), postoperative adjuvant therapy (P=0.017), operative time (P=0.013), blood loss (P=0.038), anus-preserver (P=0.048), 30-day complication rate (P=0.000), time to flatus (P=0.036), hospital stays (P=0.011), distance from the anus (P=0.047), tumor size (P=0.002), mitotic count (P=0.035) and National Institutes of Health (NIH) criteria (P=0.000) were significantly different between these two groups (all P<0.05). The median follow-up time was 41 (range, 1–122) months. Twelve patients had recurrence and metastasis, and 4 patients died. The 5-year disease-free survival (DFS) and overall survival (OS) were 74.4% and 91.2%, respectively, in the whole group. There were no statistically significant differences between the TA group and the NTA group at 5-year DFS (81.3% vs. 79.0%, P=0.243) and OS (88.7% vs. 93.3%, P=0.308). Conclusions In the treatment of rectal GIST, TA resection has a minimally invasive effect, less postoperative complications, high anal sphincter preservation rate, and R0 resection rate and a better prognosis. How to improve the proportion of neoadjuvant therapy and choose the appropriate cases for TA surgery is still a challenge.

[1]  J. Blay,et al.  Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives. , 2019, Translational gastroenterology and hepatology.

[2]  T. Hinojosa,et al.  Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database , 2019, Journal of Racial and Ethnic Health Disparities.

[3]  C. Antonescu,et al.  Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras , 2019, Annals of surgery.

[4]  B. Baca,et al.  Complete response after neoadjuvant treatment for rectal cancer , 2019, The Lancet.

[5]  Nicolas Patel,et al.  Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States , 2019, Cureus.

[6]  Tao Zhang,et al.  Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer: A Systematic Review and Meta-Analysis , 2019, Journal of Cancer.

[7]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[8]  C. Raut,et al.  Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial , 2018, JAMA oncology.

[9]  P. Zhang,et al.  Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review , 2018, Surgical Endoscopy.

[10]  K. Hata,et al.  Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors , 2018, Surgery Today.

[11]  M. Lux,et al.  Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis , 2018, Breast Cancer Research and Treatment.

[12]  Robin L. Jones,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Yuichiro Kato,et al.  [Resection of an Advanced Rectal Gastrointestinal Stromal Tumor Following Neoadjuvant Chemotherapy]. , 2018, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  T. Wakai,et al.  Management of rectal gastrointestinal stromal tumor. , 2018, Translational gastroenterology and hepatology.

[15]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  C. Antonescu,et al.  Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome , 2017, Annals of Surgical Oncology.

[17]  W. Elkashef,et al.  Resection of rectal GIST using a novel technique: a report of two cases , 2017, Ecancermedicalscience.

[18]  L. Shen,et al.  Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[19]  T. Sakurai,et al.  Transanal total mesorectal excision for a large leiomyosarcoma at the lower rectum: a case report and literature review , 2017, Surgical Case Reports.

[20]  Katerina O. Wells,et al.  Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases , 2017, Annals of Surgical Oncology.

[21]  J. Pintor-Tortolero,et al.  Transanal minimally invasive surgery approach for rectal GIST , 2016, Techniques in Coloproctology.

[22]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  C. Fisher,et al.  Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib , 2015, The British journal of surgery.

[24]  Heli Liu,et al.  Treatment strategy of rectal gastrointestinal stromal tumor (GIST) , 2014, Journal of surgical oncology.

[25]  F. van Coevorden,et al.  Surgical management of rectal gastrointestinal stromal tumors , 2013, Journal of surgical oncology.

[26]  C. Mussi,et al.  Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib , 2013, Annals of Surgical Oncology.

[27]  Ming-he Wang,et al.  Clinicopathological Features and Prognostic Factors of Rectal Gastrointestinal Stromal Tumors , 2013, Journal of Gastrointestinal Surgery.

[28]  Yingyong Hou,et al.  Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. , 2009, World journal of gastroenterology.

[29]  C. Dong,et al.  Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysis , 2007, Scandinavian journal of gastroenterology.

[30]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[31]  Jinn Shiun Chen,et al.  Evaluation of Prognosis for Malignant Rectal Gastrointestinal Stromal Tumor by Clinical Parameters and Immunohistochemical Staining , 2004, Diseases of the colon and rectum.